Search results
Showing 61 to 75 of 687 results for must
Transient loss of consciousness ('blackouts') in over 16s (CG109)
This guideline covers assessment, diagnosis and referral for people over 16 who have had a transient loss of consciousness (TLoC; also called a blackout). It aims to improve care for people with TLoC by specifying the most effective assessments and recommending when to refer to a specialist.
Diabetes: structured education within 12 months of diagnosis (IND11)
This indicator covers the proportion of adults with diabetes referred to a structured education programme within 12 months of diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG14
User guide for the cost comparison company evidence submission template (PMG32)
This user guide describes how to submit evidence to NICE when a cost-comparison case is made as part of the fast track technology appraisal process. It explains what information NICE requires and the format in which it should be presented
This indicator covers the percentage of patients aged 18 or over on drug treatment for epilepsy who have been seizure free for the last 12 months recorded in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM110
incidence and rate of renal replacement therapy after using contrast media. This must include people with stage 4 chronic kidney disease...
Restless legs syndrome: Oxycodone/naloxone prolonged release (ESNM67)
Summary of the evidence on oxycodone/naloxone prolonged release for treating restless leg syndrome (RLS) to inform local NHS planning and decision-making
We are listening to your views on this Technology appraisal guidance. Comments close 9 January 2026.
Pharmalgen for the treatment of bee and wasp venom allergy: review proposal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 9 January 2026.
Evidence-based recommendations on bimekizumab (Bimzelx) for treating active psoriatic arthritis in adults.
Guidance on the use of electroconvulsive therapy: review proposal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 16 January 2026.
Evidence-based recommendations on tirzepatide (Mounjaro) for managing overweight and obesity in adults.
Opioid dependence: buprenorphine prolonged-release injection (Buvidal) (ES19)
Summary of the evidence on buprenorphine prolonged-release subcutaneous injection (Buvidal) for opioid dependence to inform local NHS
Sunitinib for the treatment of gastrointestinal stromal tumours (TA179)
Evidence-based recommendations on sunitinib (Sutent) for treating gastrointestinal stromal tumours in adults.
Depression and anxiety: biopsychosocial assessment at diagnosis (IND103)
This indicator covers the percentage of patients with a new diagnosis of depression in the preceding 1 April to 31 March who have had a bio-psychosocial assessment by the point of diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM49
Evidence-based recommendations on nusinersen (Spinraza) for treating spinal muscular atrophy in children and adults.